ARHGEF9-IT1

Across TCGA pan-cancer cohorts, ARHGEF9-IT1 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ARHGEF9-IT1’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where ARHGEF9-IT1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ARHGEF9-IT1 is over-expressed in tumor.

COAD, BRCA, and LUSC are the cancer types where ARHGEF9-IT1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARHGEF9-IT1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	All	+0.197	.008	4	view →
BRCA	Female	All	+0.136	.019	4	view →
LUSC	Male	II,III,IV	+0.070	.013	2	view →
LUAD	All	All	+0.159	.043	1	view →
ESCA	All	All	+0.106	.027	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

ARHGEF9-IT1–COAD

Open the COAD breakdown →